St. Jude faces shareholder suit over Riata; Bard suffers setback in patent suit against Gore;

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: Tijuana is now a booming medical device industry cluster. Article | Follow @MarkHFierce

 @DamianFierce: We all know how devicemakers hate the potential 2.3% tax, but might they be exaggerating the pain? News | Follow @DamianFierce

> St. Jude Medical ($STJ) faces a shareholder class action lawsuit for failing to disclose the full extent of the problems with its now-recalled Riata leads, which resulted, the suit alleges, in an inflated share price. Story

> C. R. Bard is facing a partial setback in a patent infringement case against W. L. Gore. The U.S. Court of Appeals for the Federal Circuit has reversed part of its previous ruling awarding $317 million to Bard in the case. Report

> Pittsburgh's ALung got some positive results from clinical trials of the Hemolung respiratory assist system, a respiratory dialysis system designed to treat COPD. More

> T2 Biosystems is preparing to present data on its new endotoxin-detecting assay for injectables at the American Society for Microbiology General Meeting this week in San Francisco. Release

Biotech News

 @FierceBiotech: The Fierce team has landed in Boston. Check out our dedicated BIO2012 page. Special Coverage | Follow @FierceBiotech

 @JohnCFierce: Quintiles (CRO) is expanding in China, building a regional HQ in Shanghai. Release | Follow @JohnCFierce

 @RyanMFierce: Roche does an encore Alzheimer's deal with AC Immune worth up to $420M, focused on anti-Tau antibodies. More | Follow @RyanMFierce

> BIO's James Greenwood sees industry optimism returning. Report

> Roche snags another Alzheimer's antibody from AC Immune in $418M-plus deal. News

> Ambrx inks $303M 'smart bomb' development pact with Merck. More

> Infinity Pharma writes off lead drug after two more failed studies. Article

Pharma News

 @FiercePharma: China's pharma industry blames toxic capsules on super-aggressive tendering, says corner-cutting won't stop. Report | Follow @FiercePharma

> FDA keeps door open to pharmacy versions of KV's Makena. More

> Biotest prepared to exit Greece for non-payment. Story

> Cipla chief aims for more cut-rate cancer drugs. Article

Biotech IT News

> Harvard IDs key human-hosted bugs with computer systems. More

> Third Rock fuels $41M launch of Bay Area biotech. Item

> Africa goes mobile to tackle drug safety woes. Story

And Finally... Minnesota, with its huge stake in the medical devices industry, has become something of a ground zero for debate over the proposed 2.3% tax. Last week, a member of a local biotech trade group wrote an anti-tax editorial in the Star Tribune. This week, the publisher of a Minnesota-based health website called his claims "outlandish." News